Literature DB >> 17969092

Treatment of addictive behaviors in liver transplant patients.

Robert M Weinrieb1, Michael R Lucey.   

Abstract

Very little addiction treatment research has been done concerning smoking cessation, illicit drugs, or even alcohol abuse in liver transplant patients. Our data suggest that a surprising number of patients who are awaiting a liver transplant for alcohol-related end-stage liver disease will return to drinking before transplantation. We found that motivational enhancement therapy afforded no marked benefit over treatment as usual for drinking, smoking, mood, or general health outcomes in alcoholics awaiting liver transplantation. Stably abstinent methadone-maintained opiate-dependent patients should not be tapered off methadone; are generally good candidates for liver transplant; show low relapse rates into illicit use of opiates; and may be at risk for more medical complications than their counterparts. Pre- and posttransplantation smoking rates are high and cause marked morbidity and mortality. Transplant teams should encourage smoking cessation treatments.Marijuana use in liver transplant recipients is not uncommon, and apart from the risk of developing aspergillosis, additional health risks have not yet been identified.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17969092     DOI: 10.1002/lt.21340

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  4 in total

Review 1.  Substance use disorders before and after liver transplantation.

Authors:  Jason L Eccleston; Michael R Lucey
Journal:  Clin Liver Dis (Hoboken)       Date:  2017-10-31

2.  Clinical Practice Guidelines for Liver Transplantation in Saudi Arabia.

Authors:  Faisal A Abaalkhail; Mohammed I Al Sebayel; Mohammed A Shagrani; Wael A O'Hali; Nasser M Almasri; Abduljaleel A Alalwan; Mohammed Y Alghamdi; Hamad Al-Bahili; Mohammed S AlQahtani; Saleh I Alabbad; Waleed K Al-Hamoudi; Saleh A Alqahtani
Journal:  Saudi Med J       Date:  2021-09       Impact factor: 1.422

3.  Inhaled medicinal cannabis and the immunocompromised patient.

Authors:  Rosa Ruchlemer; Michal Amit-Kohn; David Raveh; Lumír Hanuš
Journal:  Support Care Cancer       Date:  2014-09-13       Impact factor: 3.603

Review 4.  Addictive behaviors in liver transplant recipients: The real problem?

Authors:  Hélène Donnadieu-Rigole; Pascal Perney; José Ursic-Bedoya; Stéphanie Faure; Georges-Philippe Pageaux
Journal:  World J Hepatol       Date:  2017-08-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.